The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”
The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”
Aim: The purpose of the study was to investigate the effective prognostic factors on recurrence and mortality in patients withdifferential thyroid cancer.Material and Methods: The effects of various parameters of demographic characteristics, the admission symptoms, physicalexamination, laboratory findings, pathological examination, and surgical method of 184 patients, who underwent surgery due todifferential thyroid cancer between January 1986 and December 2009 in 4th General Surgical Clinic of Ankara Numune Trainingand Research Hospital, on prognosis were examined. The information of the patients was obtained from automation system ofthe hospital and Thyroid Cancer Information and Follow-Up Form of 4th General Surgical Clinic of Ankara Numune Training andResearch Hospital.Results: The sample group consisted of 172 papillary cancer patients and 12 follicular cancer patients. The mean age of the patientswas 45.4 years (15-78). There were 159 (86.4%) female patients and 25 (13.6%) male patients. The mean follow-up period of 161(87.5%) patients, who were followed up regularly, was 73.26 months (1-231). The mean recurrence period was 77.66 months (1-150).Mortality was observed in eight (4.3%) patients during their follow-up period. The mean life expectancy of those who died was 66.87months (1-150 months).*Single variable analysis revealed that the T stage and pathologic final stage were effective on recurrence. Painful nodules andpalpable lymph nodes in the neck and the papillary histological malignant subtype variant, as well as the presence of vascular andadjacent organ invasion, multicentricity, T stage, the lymph nodes, distant metastasis, and the clinical stage during the admissionwere identified to be effective on mortality.Conclusion: The risk of recurrence is high in DTC patients with high T stage and advanced pathologic stage. The rate of survival ofthose with multicentric tumors and advanced pathologic stage is low. Therefore, it is important for patients to be followed up closelywithin a postoperative multidisciplinary context.
___
- 1. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer
Data Base report on 53,856 cases of thyroid carcinoma
treated in the U.S., 1985-1995. Cancer 1998;83:2638-48.
- 2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA
Cancer J Clin 2009;59:225-49.
- 3. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer
Statistics Review, 1975-2006, National Cancer Institute.
Bethesda, MD, http://seer.cancer.gov/csr/1975-2006/,
based on November 2008 SEER data submission, posted to
the SEER, 2009.
- 4. Wu XC, Chen VW, Steele B, et al. Cancer incidence in
adolescents and young adults in the United States, 1992-
1997. J Adolesc Health 2003;32:405-15.
- 5. Wu X, Groves FD, McLaughin CC, et al. Cancer incidence
patterns among adolescents and young adults in the United
States. Cancer Causes Control 2005;16:309-20.
- 6. Bleyer A, Viny A, Barr R. Cancer in 15- to 29-year-olds by
primary site. Oncologist 2006;11:590-60.
- 7. Mazzaferri EL, Jhiang SM. Long-term impact of initial
surgical and medical therapy on papillary and follicular
thyroid cancer. Am J Med 1994;97:418-28.
- 8. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after
exposure to external radiation: a pooled analysis of seven
studies. Radiat Res 1995;141:259-77.
- 9. Mazzaferri EL, Jhiang SM. Differentiated thyroid cancer
long-term impact of initial therapy. Trans Am Clin Climatol
Assoc 1995;106:151-70.
- 10. Cheung CC, Ezzat S, Freeman JL, et al. Imunohistochemical
diagnosis of papillary thyroid carcinoma. Mod Pathol
2001;14:338-42.
- 11. Clark OH. Total thyroidectomy: the treatment of choice
for patients with differentiated thyroid cancer. Ann Surg
1982;:361-70.
- 12. Emerick GT, Duh Q-Y, Siperstein AE, et al. Diagnosis,
treatment, and outcome of follicular thyroid carcinoma.
Cancer 1993;72:3287-95.
- 13. Pasieka JL, Thompson NW, McLeod MK, et al. The incidence
of bilateral well-differantiated thyroid cancer found at
completion thyroidectomy. World J Surg 1992;16:711-16.
- 14. Scheumann GF, Seeliger H, Musholt TJ et al. Completion
thyroidectomy in 131 patients with differentiated thyroid
carcinoma. Eur J Surg 1996;162:677-84.
- 15. Chao TC, Jeng LB, Lİn JD, et al. Completion thyroidectomy
for differentiated thyroid carcinoma. Otolaryngol Head ang
Neck Surg 1998;118:896-9.
- 16. Pacini F, Elisei R, Capezzone M, et al. Contralateral papillary
thyroid cancer is frequent at completion thyroidectomywith
no difference in low- and high-risk patients. Thyroid
2001;11:877-81.
- 17. Dean DS, Hay ID. Prognostic indicators in differentiated
thyroid carcinoma. Cancer Control: JMCC 2000;7:229-39.
- 18. Baker RR, Hyland J. Papillary carcinoma of the thyroid gland.
Surg Gynaecol Obstet 1985;161:546-50.
- 19. Mazzaferi EL. Thyroid carcinoma: papillary and follicular. In:
Mazzaferi EL, Saaman N, eds. Endocrine Tumors. Cambridge:
Blackwell Scientific Publications; 1993. p. 278-333.
- 20. Sherman SI. Thyroid Carcinoma (Seminar). Lancet
2003;361:501-11.
- 21. LiVolsi VA. Unusual variants of papillary thyroid carcinoma,
in Mazzaferri EL, Kreisberg RA, Bar RS, editon. Adv Endocrinol
Metab. St. Louis, Mosby- Year Book, 1995;39-54.
- 22. Salvesen H, Njolstad PR, Akslen LA, et al. Papillary thyroid
carcinoma: A multivariate analysis of prognostic factors
including an evaluation of the p-TNM staging system. Eur J
Surg 1992;158:583-9.
- 23. Crile GJ, Hazard JB. Relationship of the age of the patient
to the natural history and prognosis of carcinoma of the
thyroid. Ann Surg 1953;138:33-8.
- 24. Frankenthaler RA, Sellin RV, Cangir A, et al. Lymph node
metastasis from papillary follicular thyroid carcinoma in
young patients. Am J Surg 1990;160:341-3.
- 25. Schlumberger M, De Vathaire F, et al. Differentiated thyroid
carcinoma in childhood: long term follow-up of 72 patients.
J Clin Endocrinol Metab 1987;65:1088-94.
- 26. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome
in papillary thyroid carcinoma: development of a reliable
prognostic scoring system is a cohort of 1779 patients
surgically treated at one institution during 1940 through
1989. Surg 1993;114:1050-58.
- 27. Tsang RW, Brierley JD, Simpson WJ, et al. The effects of
surgery, radioiodine, and external radiation therapy on the
clinical outcome of patients with differentiated thyroid
carcinoma. Cancer 1998, 82:375-88.
- 28. Yamashita H, Noguchi S, Murakami N, et al. Extracapsular
invasion of lymph node metastasis is an indicator of distant
metastasis and poor prognosis in patients with thyroid
papillary carcinoma. Cancer 1997;80:2268-72.
- 29. Mazzaferri EL. Management of a solitary thyroid nodule. N
Engl J Med 1993;328:553-9.
- 30. Mazzaferri EL, Kloos RT. Using recombinant human TSH
in the management of well-differentiated thyroid cancer:
current strategies and future directions. Thyroid 2000,
10:767-78.
- 31. Loh KC, Greenspan FS, Gee L, et al. Pathological Tumor-
Node-Metastasis (pTNM) staging for papillary and follicular
thyroid carcinomas: a retrospective analysis of 700 patients.
J Clin Endocrinol Metab 1997;82:3553–62.
- 32. Passler C, Prager G, Scheuba C, et al. Application of Staging
Systems for Differentiated Thyroid Carcinoma in an Endemic
Goiter Region With Iodine Substitution. Annals of Surg
2003;237:227-34.